摘要
目的：回顾性分析299例复治晚期非小细胞肺癌患者接受埃克替尼治疗的疗效和安全性。方法：299例经病理学或细胞学证实的复治ⅢB～Ⅳ期非小细胞肺癌患者口服埃克替尼125 mg/次，3次/d，直至疾病进展或出现严重不良反应。评价埃克替尼的疗效和不良反应。结果：299例患者的客观缓解率和疾病控制率分别为18.4%（55/299）和72.2%（216/299），中位无进展生存（progression-free survival，PFS）期为4.2个月，中位总生存（overall survival，OS）期为12.6个月，1年生存率为52.3%。43例表皮生长因子受体（epidermal growth factor receptor，EGFR）基因突变患者的中位PFS期为8.7个月，中位OS期未达到；34例野生型患者的中位PFS期为2.6个月，中位OS期为10.3个月。患者的不良反应以皮疹和腹泻为主，多为Ⅰ～Ⅱ度。结论：埃克替尼对既往化疗失败的局部晚期或转移性非小细胞肺癌患者具有较好的疗效，且不良反应多可耐受。
Objective： This retrospective study aimed to evaluate the efficacy and tolerability for 299 advanced non-small cell lung cancer （NSCLC） patients who had failed one or more chemotherapy before receiving icotinib. Methods： Two hundred ninety-nine patients with cytologically or histologically confirmed stage ⅢB or Ⅳ NSCLC who had failed chemotherapy were treated with icotinib in Zhejiang Cancer Hospital until the disease progressed or severe adverse events occurred. The efficacy and tolerability of icotinib was evaluated . Results： The overall objective response rate （ORR） and the disease control rate （DCR） of 299 patients were 18.4% （55/299） and 72.2% （216/299）, respectively. The median progression-free survival （PFS） was 4.2 months, and the median overall survival （OS） was 12.6 months. The median PFS of 43 patientsin with epidermal growth factor receptor （EGFR） mutation was 8.7 months and the median OS was not reached. The median PFS was 2.6 months and the median OS was 10.3 months in 34 patients with wild-type EGFR. Most of icotinib-related adverse events were skin rash and diarrhea （grade Ⅰ/Ⅱ） and reversible. Conclusion： Icotinib monotherapy has significant antitumor activity in advanced NSCLC patients who failed one or more chemotherapy before receiving icotinib. The toxicities are well tolerated and acceptable.
出处
《肿瘤》
CAS
CSCD
北大核心
2014年第7期629-635,共7页
Tumor
关键词
癌
非小细胞肺
埃克替尼
靶向治疗
疗效
安全性
Carcinoma, non-small cell lung
Icotinib
Targeted therapy
Efficacy
Safety
